Editorial Board

Dr. Susan M. Webb is Emeritus Professor of Medicine at the Autonomous University of Barcelona and Honorary Senior Consultant Endocrinologist at Hospital Sant Pau, Barcelona, Spain where she created the Neuroendocrine Clinic; her research group on Pituitary Diseases is part of the Spanish Network of Excellence of Rare Diseases (CIBERER Unit 747). She is interested in the long-term consequences of pituitary diseases and evaluation of health-related quality of life.

Dr. Webb earned her medical degree from the University of Barcelona Medical School and completed her residency in endocrinology at the Hospital Clinic in Barcelona, Spain. She undertook her Clinical Research Fellowship at St. Bartholomew’s Hospital, London, UK, and was a Fulbright Scholar for Reproductive Neuroendocrinology in San Antonio, Texas, USA during the period 1983-1984.

Dr Webb coordinates the European Registry on Cushing’s Syndrome (ERCUSYN), initially financed by the European Union 2007̶ 2010, which includes data from over 2000 patients. She has been President of the Spanish Society of Endocrinology and Nutrition, Secretary of the European Neuroendocrine Association and, until 2018, a member of the Executive Committee of the European Society of Endocrinology.

Dr Webb has been an editorial board member for The Journal of Clinical Endocrinology & Metabolism, Pituitary, Endocrine, Medicina Clínica and Endocrinología, Nutrición y Diabetes, among other journals. She has been a member of the European Union Committee of Experts on Rare Diseases (EUCERD), and is currently Scientific Deputy Director of CIBERER and President of the Rare Diseases Advisory Committee of the Catalan health system, CatSalut. She has supervised more than 20 doctoral theses and has co-authored more than 400 publications. In 2019, the group she was leading was designated a reference center for pituitary diseases (CSUR – centro, servicio o unidad de referencia) by the Spanish Ministry of Health which, in 2022, became part of the European Network for Rare Diseases (RareEndoERN). She has extensive clinical experience in neuroendocrine disorders, has been in receipt of over 40 grants, and has served as the principal investigator of numerous clinical trials.

Dr Webb has received awards for teaching and clinical investigation from the European Society of Endocrinology (Clinical Endocrinology Trust Award, 2019) and the European Neuroendocrine Association (Rolf Gaillard Award, 2019).

Disclosures: Dr Webb is on the Scientific Advisory Boards of Novartis, Ipsen, Recordati Rare Diseases and HRA Pharma Rare Diseases. She has received speaker fees from Ipsen, HRA Pharma Rare Diseases, Recordati Rare Diseases and Consilient Health. Dr Webb has received unrestricted research funds from Pfizer and HRA Pharma Rare Diseases and has assisted with clinical trials for Novartis, Recordati Rare Diseases and Cortendo.

Iacopo Chiodini’s research career commenced in 1994, since which he has largely focused on the influence of endocrine disorders on bone metabolism, particularly in relation to overt and subclinical hypercortisolism. He is currently focusing on the diagnosis and therapy of subclinical hypercortisolism, the role of cortisol secretion in hypertension, diabetes and osteoporosis, and the involvement of bone in metabolic syndrome.

Iacopo Chiodini is co-author of more than 170 peer-reviewed papers (Scopus h-index 44). He has coordinated several studies on the effects of subclinical hypercortisolism in patients with adrenal incidentalomas, the role of the hypothalamic-pituitary-adrenal axis, and individual sensitivity to glucocorticoid excess in patients with diabetes and osteoporosis, as well as the effects of conservative or surgical approaches to treatment in patients with mild hypercortisolism. He is currently involved with several drug-development trials for the treatment of both overt and subclinical hypercortisolism and is a member of advisory boards that focus on hypercortisolism screening in high-risk populations.

Iacopo Chiodini has been speaker, or Chair, at more than 130 national and international meetings and Visiting Professor for subclinical hypercortisolism and adrenal incidentalomas at several renowned US institutions. These include the University of Central Florida, Orlando, FL; University of Michigan, Ann Arbor, MI; University of Arizona, Phoenix, AZ; Oregon Health & Science University, Portland, OR; University of California, Sacramento and San Diego, CA; Johns Hopkins Hospital, Baltimore, MD; Mount Sinai Hospital, New York, NY; and the Medical College of Wisconsin, Milwaukee, WI.

Iacopo Chiodini is Editor-in-Chief of the journal section Adrenal Endocrinology in Frontiers in Endocrinology and a member of the adrenal incidentaloma study group of ENS@T (the European Network for the Study of Adrenal Tumors). He is current President of the Italian Society for Osteoporosis and Metabolic Bone Diseases.

Disclosures: Iacopo Chiodini has served on advisory boards for HRA Pharma Rare Diseases, Corcept Therapeutics, Eli-Lilly, Amgen, UCB, Abiogen, Theramex, and Sandoz and is currently involved with clinical trials for HRA Pharma Rare Diseases, and Corcept Therapeutics.